20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy
20/20 Biolabs Inc AIDX
$0.43
▲ +5.98%
(+$0.02)
Open
$0.43
Prev Close
$0.40
Day Range
$0.42 – $0.44
52W Range
$0.43 – $50.00
Market Cap
$5.21M
Beta
2.41
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-09-08 |
| Shares Out. | 12,250,000 |
| Website | 2020gene.com/ ↗ |
| Phone | 12404536339 |
| Employees | 14 |
| Revenue | $353,375 |
| Gross Profit | $62,884 |
| Net Income | -$2.2M |
| Total Assets | $5.8M |
| Total Liabilities | $3.0M |
| Equity | $2.6M |
About 20/20 Biolabs Inc
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
20/20 Biolabs Inc is a publicly traded company under the ticker symbol AIDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.